Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Global Research Solutions Corp

Neither a doctor nor a teaching hospital

Research payments

$5,692,972

1,265 payments

Through program year 2025, Global Research Solutions Corp is reported as receiving $5,692,972 in research payments, across 1,265 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,904 1
2024 Research $2,113,510 886
2023 Research $1,067,372 281
2022 Research $317,535 37
2021 Research $214,914 23
2020 Research $350,023 14
2019 Research $1,620,714 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Chiesi USA, Inc. $2,868,762 104 payments
  2. Cipla USA Inc. $2,251,474 1,084 payments
  3. GlaxoSmithKline, LLC. $560,694 60 payments
  4. Regeneron Pharmaceuticals, Inc. $12,041 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. U-Fs-Mu-As3120 $1,635,372 17 payments
  2. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $994,274 12 payments
  3. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $460,836 11 payments
  4. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $423,355 17 payments
  5. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $293,145 4 payments
  6. A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER) $261,013 19 payments
  7. A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $225,578 24 payments
  8. A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-Week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 Micro GM Inhalation Powder With Advair Diskus 100/50 Micro GM in Asthma Patients $222,797 9 payments
  9. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $160,796 16 payments
  10. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $125,683 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record